The recommended backbone treatment for KRAS-mutant colorectal cancer included a fluoropyrimidine-based regimen in combination with oxaliplatin and/or irinotecan and the addition of an anti-VEGF in the first and second line [2]. Here, KRAS is linked to colorectal cancer.